Drug Trial Radar · NCT04742959
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
203
Actual
Start
Mar 14, 2021
Primary completion
Feb 20, 2024
Study completion Feb 20, 2024
Sponsor
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Cholangiocarcinoma
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Bladder Cancer
- Small-cell Lung Cancer
- Prostate Cancer
- Thyroid Cancer
- Sarcoma
- Gastric Cancer
- Gallbladder Cancer
Interventions
TT-00420Drug
TT-00420 tablet will be administered orally once daily per protocol defined schedule.
Nab-PaclitaxelCombination product
Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: Up to 30 days from study discontinuation
- Dose limiting toxicity (DLT)Time frame: Up to 28 days from the first dose
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
The University of Chicago
Chicago, Illinois
Rutgers Cancer Institute
New Brunswick, New Jersey
Gabrail Cancer Center Research
Canton, Ohio
UT Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.